Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) FCF Margin (2016 - 2025)

Amphastar Pharmaceuticals has reported FCF Margin over the past 13 years, most recently at 17.29% for Q4 2025.

  • Quarterly results put FCF Margin at 17.29% for Q4 2025, up 838.0% from a year ago — trailing twelve months through Dec 2025 was 20.61% (down 293.0% YoY), and the annual figure for FY2025 was 20.61%, down 293.0%.
  • FCF Margin for Q4 2025 was 17.29% at Amphastar Pharmaceuticals, down from 27.16% in the prior quarter.
  • Over the last five years, FCF Margin for AMPH hit a ceiling of 42.63% in Q4 2021 and a floor of 5.51% in Q4 2023.
  • Median FCF Margin over the past 5 years was 24.16% (2022), compared with a mean of 20.2%.
  • Biggest five-year swings in FCF Margin: crashed -4661bps in 2022 and later skyrocketed 4055bps in 2023.
  • Amphastar Pharmaceuticals' FCF Margin stood at 42.63% in 2021, then plummeted by -109bps to 3.98% in 2022, then tumbled by -38bps to 5.51% in 2023, then skyrocketed by 262bps to 8.91% in 2024, then soared by 94bps to 17.29% in 2025.
  • The last three reported values for FCF Margin were 17.29% (Q4 2025), 27.16% (Q3 2025), and 23.07% (Q2 2025) per Business Quant data.